相关的SCN2A-L1342P突变导致网络过度兴奋和人类皮质器官的广泛转录变化
bioRxiv : the preprint server for biology
|September 2, 2025
概括
SCN2A-L1342P突变通过增加人类皮质器官中的神经元刺激性和突触活性引起. 这导致网络过度刺激,并破坏关键的发育和突触通路,为发育和脑病 (DEE) 提供了洞察力.
科学领域:
- 神经科学
- 遗传学
- 干细胞生物学
背景情况:
- 病原性SCN2A突变是的单一原因.
- Nav1. 2- L1342P突变是一种与有关的复发性异构突变.
研究的目的:
- 使用人类诱导多能干细胞 (iPSC) 模型研究SCN2A-L1342P相关的分子和细胞机制.
- 在携带Nav1.2-L1342P突变的3D皮质器官中描述疾病表型.
主要方法:
- 从具有 Nav1.2-L1342P 突变的人类男性 iPSC 参考线 (KOLF) 中生成 3D 皮质器官.
- 使用补丁和多电极阵列 (MEA) 记录的功能研究.
- 通过免疫细胞化学和RNA测序进行表征.
主要成果:
- 在Nav1.2-L1342P有机体中,神经元表现出增加的内在激发能力和放大激发后突触电流.
- 观察到网络点火活动增加和网络过度刺激.
- 转录基因分析显示了突触,谷氨酸和发育途径的显著变化,包括细胞衰老和细胞亡的增强.
结论:
- Nav1. 2- L1342P突变诱导了多方面的疾病表型,包括神经元和突触功能障碍,导致网络过度刺激.
- 这些发现有助于了解SCN2A相关的发育性和性脑病 (DEE).
- 这项研究为开发与SCN2A相关的个性化干预提供了基础.
更多相关视频
08:04Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
492
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
12.2K
相关概念视频
Epilepsy and Seizures: Overview
275
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
275
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
445
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
445
